Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CA91911K1021
Ticker VRX
Company VALEANT PHARMACEUTICALS INTERNATIONAL
Currency $
Price
Aware Investor Index (AII) 0.0000
Recommendation STRONG SELL
P/E 239.46
ROE 1.20 %
Capitalization 15,616,795,000 $
Dividend Yield 0.00 %
P/S 1.89
AII Position 776
P/E Position 766
ROE Position 779
Capitalization Position 415
Dividend Yield Position 629
Sales 8,263,500,000 $
10-Year Average Earnings 65,217,000 $
Shares Outstanding 341,500,000
Equity 5,434,500,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country Canada
VALEANT PHARMACEUTICALS INTERNATIONAL Investor Relations Web Site http://ir.valeant.com







Sales:

YEAR MONTH AMOUNT
2014 12 8,263,500,000.00 $
2013 12 5,769,605,000.00 $

Earnings:

YEAR MONTH AMOUNT
2014 12 913,500,000.00 $
2013 12 -866,142,000.00 $
2012 12 -116,025,000.00 $
2011 12 159,559,000.00 $
2010 12 -208,193,000.00 $
2009 12 176,455,000.00 $
2008 12 199,904,000.00 $
2007 12 103,541,000.00 $
2006 12 228,939,000.00 $
2005 12 60,632,000.00 $

Equity:

YEAR MONTH AMOUNT
2014 12 5,434,500,000.00 $
2013 12 5,233,322,000.00 $
2012 12 3,717,398,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2014 12 341,500,000
2013 12 320,996,000
2012 12 303,861,000

 












Bloomberg News for VALEANT PHARMACEUTICALS INTERNATIONAL:

Jan 6, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1500 CVE CENOVUS ENE CVE US 03/19/11 C22.5 17.3 55.9 10.30 -5.5 500 VRX VALEANT PHA VRX US 01/22/11 C32 17.1 38.9 3.30 407.7 1291 CSX CSX CORP CSX US 01/22/11...
Jan 3, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1368 SSO PROSHARES U SSO US 01/22/11 C40 16.9 53.7 9.27 14.4 517 VRX VALEANT PHA VRX US 01/22/11 C26 16.8 47.4 3.05 -7.6 1000 CSCO CISCO SYSTE CSCO US 01/22/11...
Dec 1, 2003
A New Way To Fight Hepatitis C
better at bypassing the blood cells and going straight to the liver. Valeant Pharmaceuticals (VRX), formerly ICN Pharma-ceuticals (ICN), developed both drugs. And it announced in early November...
Sep 28, 2011
Allon, PetroAmerica, Rare Element, TMX: Canadian Equity Preview
offered to buy TMX for C$3.73 billion ($3.65 billion). Valeant Pharmaceuticals International Inc. (VRX CN): The drugmaker received approval for colesevelam hydrochloride, a treatment to help lower LDL...
Aug 4, 2011
Iridian Asset Mgmt Holdings in 2nd Quarter: 13F Alert
(USD $) Position In Position Valeant Pharmaceuticals Inte VRX US 295,603,506 5,689,059 -1,052,171 Wyndham Worldwide Corp WYN US 274,946...
Apr 21, 2011
ARC Resources, Celestica, Silver Wheaton: Canada Equity Preview
Steven Butler, an analyst at Canaccord Financial Inc. Valeant Pharmaceuticals International Inc. (VRX CN): Canada‚Äôs largest drugmaker said it is prepared to ‚Äúmodestly‚ÄĚ raise its bid for Cephalon Inc...
Feb 14, 2011
Brahman Capital Corp Largest Holdings in 4th Quarter: 13F Alert
Technologies Holding ST US 70,728,842 2,349,015 2,349,015 Valeant Pharmaceuticals Inte VRX US 65,248,056 2,306,400 -254,700 Xerox Corp XRX US 57,273...
Feb 15, 2011
ValueAct Holdings Largest Holdings in 4th Qtr: 13F Alert
(USD $) Position In Position Valeant Pharmaceuticals Inte VRX US 762,695,599 26,959,901 Sara Lee Corp SLE US 611,428...
May 24, 2011
Eastplats, National Bank of Canada: Canadian Equity Preview
Mario Mendonca, an analyst at Canaccord Financial Inc. Valeant Pharmaceuticals International Inc. (VRX CN): Canada’s biggest drugmaker agreed to buy Lithuania-based AB Sanitas for about 314 million...
Feb 27, 2006
In India, Selling Generics Used To Be So Easy
Jersey, and bought an Ohio factory from California-based Valeant Pharmaceuticals International (VRX ). In December, Bombay's Glenmark Pharmaceuticals announced a deal with InvaGen Pharmaceuticals...


Google News for VALEANT PHARMACEUTICALS INTERNATIONAL:

Nasdaq - 6 days ago
Valeant Pharmaceuticals International Breaks Below 200-Day ...
In trading on Friday, shares of Valeant Pharmaceuticals International Inc (Symbol: VRX) crossed below their 200 day moving average of $13.67 ...
StandardOracle
Relative Strength Index for Valeant Pharmaceuticals International ...
Valeant Pharmaceuticals International, Inc. (VRX) lost -3.28% to reach $12.39 in the previous trading session. Overall, 15.44 Million shares ...
StockNewsGazette
Analyst Commentary On Valeant Pharmaceuticals International, Inc ...
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is struggling to gain traction with investors, as evidenced by its 15.44 million shares ...
Seeking Alpha
Valeant Pharmaceuticals International, Inc. (VRX) , Cenovus Energy ...
On Wednesday trading day Valeant Pharmaceuticals International, Inc. (VRX) stock showed the move of -3.28% with the closing price of $12.39 ...
StandardOracle - 4 hours ago
Should Value Investors Consider Valeant Pharmaceuticals ...
Let's put Valeant Pharmaceuticals International, Inc. VRX stock into this equation and find out if it is a good choice for value-oriented investors ...
StockNewsGazette
Valeant Pharmaceuticals International, Inc. (NYSE: VRX): Hot Mover ...
On Wednesday, Shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) expressed a change of -3.28% and closed its trade at ...
TRA
Facts About In Play Stocks: Valeant Pharmaceuticals International ...
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) has grabbed attention from the analysts when it experienced a change of -2.58% in ...
CML News
Valeant Pharmaceuticals International, Inc. (VRX) Eye-Catching ...
VRX's institutional ownership stands at 66.80%. As higher figure of institutional mostly indicates intentions of capital gain, which is suitable for ...
Post Analyst - 8 hours ago
Technical data gathered from Valeant Pharmaceuticals International ...
Technical analysis of Valeant Pharmaceuticals International, Inc. (VRX) stock includes the study of technical indicators and past trends.
StandardOracle
Valeant: Will A Key Weakness Turn Into A Strength Moving Forward?
Valeant Pharmaceuticals International, Inc. (VRX) launched Siliq (brodalumab) in late July 2017 after the FDA approved the BLA (Biologics ...


Back